Aldeyra Receives FDA Protocol Agreement to Advance ADX-2191 in Rare Eye Cancer Aldeyra Therapeutics (Nasdaq: ALDX) announced that it has received a Special Protocol Assessment (SPA) Agreement Letter from the U.S. Food and Drug Administrati

#AldeyraTherapeutics (Nasdaq: #ALDX) secures FDA Special Protocol Assessment for ADX-2191 in rare eye cancer, paving the way for potential approval in primary vitreoretinal lymphoma. Trial expected to begin in 2H 2025. .
#AldeyraALDX
prismmarketview.com/aldeyra-rece...